To Present at Noble Financial 'Double-O-Seven' Small Cap
Conference/Microcap Symposium on August 21 and Roth Capital's 2007 New York
Conference on September 5
NEWARK, Del., Aug. 15 /PRNewswire-FirstCall/ -- Strategic Diagnostics
Inc. (Nasdaq: SDIX) -- a leading provider of biotechnology-based detection
solutions for a broad range of food, water, agricultural, environmental and
life science applications, announced today that its President and Chief
Executive Officer, Matthew Knight, will present at two investor conferences
during the next three weeks.
Mr. Knight will present at Noble Research's "Two-Double-O-Seven" Small
Cap Conference/Microcap Symposium at the Charleston Place Hotel in the
heart of Charleston South Carolina's historic district. The Company will
present at 8:30 a.m. on August 21 in the Goldfinger Room with a live
webcast available at the Conference's website, http://www.two-007.net, for
approximately 30 days following the conclusion of the presentation. The
Company will have a breakout session immediately following the formal
presentation in the Diamonds are Forever room. Company management will be
available for one-on-one meetings throughout the day, which may be arranged
by emailing Noble Research at info@two-007.net.
On September 5, Mr. Knight will present at Roth Capital Partner's Roth
2007 New York Conference at the Westin Hotel in Manhattan. Mr. Knight's
presentation is scheduled for 4:30 p.m. in the Majestic II (Track 1) room.
A webcast of the presentation may be accessed at
http://www.wsw.com/webcast/roth13/sdix/ for approximately 30 days following
the conclusion of the presentation. Following the presentation, Mr. Knight
will attend a breakout session. One-on-one meetings may be scheduled
through Roth Capital Partners by calling (212) 201-2700.
Each presentation is designed to provide analysts, institutional
brokers and portfolio managers with an overview of the Company's expertise
in the production of antibodies, used both in diagnostic tests and provided
to the proteomics, pharmaceutical, diagnostics and biomedical research
industries to enable rapid discovery and commercialization of products.
Strategic Diagnostics is a leader in the food pathogen industry, providing
comprehensive, accurate, and easy-to-use tests including the recently
introduced RapidChek(R) SELECT(TM) Salmonella product. The Company is also
an emerging leader in producing monoclonal and polyclonal antibodies for
the pharmaceutical and research industries. The Company's patent-pending
technology also addresses renewable energy opportunities and can be used to
increase efficiency in the production of ethanol. Management will discuss
the recurring revenue component of the Company's business model, revenue
potential from new product and services, and the Company's strategy for
sustainable growth.
About The Noble Financial/Two-Double-O-Seven Small Cap
Conference/Microcap Symposium
Noble Financial supports emerging growth companies through strategic
advice, investment banking, market-making, sales & trading, comprehensive
equity research, and the development of institutional support. Noble's
equity conferences allow for a unique blend of professional and personal
interaction among a diverse cross-section of executives. The goal is to
deliver outstanding business organization, world-class accommodation and
meeting facilities, and memorable social events.
About the Roth Capital Partners and the 2007 New York Conference
Roth is one of the last remaining independent full-service investment
banks dedicated to the small and micro-cap market. The firm is privately
owned with current principals being majority owners. The core management
team has been consistent for many years. Since the inception of the firm in
1984, Roth has been a leader and innovator in the small and micro cap
markets. Roth's exclusive focus has been, is, and will continue to offer a
full spectrum of investment banking services, including raising capital,
research coverage, trading and market making, merger and acquisition
advisory services, and investor conferences. Roth's award-winning research
is the foundation of its firm and key to its understanding of the micro-
and small-cap sector. This research, when combined with a seasoned
institutional sales team and its highly visible investor conferences,
creates an unparalleled institutional sponsorship platform for growth
companies. Roth has raised more than $10 billion for small and micro cap
public companies and completed over 135 merger, acquisition and advisory
assignments. Since year 2000, Roth has been a leading placement agent for
the number of PIPE transactions, raising over $2 billion for its clients.
Roth received top 20 IPO aftermarket performance rankings for six
consecutive years from 1994 to 1999. The 5th Annual New York Conference is
a two-day event with more than 230 presenting companies and is attended by
over 1,200 buy side investors. The 2006 conference had more than 2,000
one-on-one meetings.
About Strategic Diagnostics Inc.
Strategic Diagnostics Inc. develops, manufactures and markets
biotechnology-based detection solutions to a diverse customer base, across
multiple industrial and human health markets. By applying its core
competency of creating custom antibodies to assay development, the Company
produces unique, sophisticated diagnostic testing and reagent systems that
are responsive to customer diagnostic and information needs. Customers
benefit with quantifiable "return on investment" by reducing time, labor,
and/or material costs. All this is accomplished while increasing accuracy,
reliability and actionability of essential test results. The Company is
focused on sustaining this competitive advantage by leveraging its
expertise in immunology, proteomics, bio-luminescence and other
bio-reactive technologies to continue its successful customer-focused
research and development efforts. Recent innovations in high throughput
production of antibodies from genetic antigens will complement the
Company's established leadership in commercial and custom antibody
production for the Research, Human/Animal Diagnostics, and Pharmaceutical
industries, and position the Company for broader participation in
proteomics research and discovery.
This news release contains forward-looking statements reflecting SDI's
current expectations. When used in this press release, the words
"anticipate", "could", "enable", "estimate", "intend", "expect", "believe",
"potential", "will", "should", "project", "plan" and similar expressions as
they relate to SDI are intended to identify said forward-looking
statements. Investors are cautioned that all forward-looking statements
involve risks and uncertainties, which may cause actual results to differ
from those anticipated by SDI at this time. Such risks and uncertainties
include, without limitation, changes in demand for products, delays in
product development, delays in market acceptance of new products, retention
of customers and employees, adequate supply of raw materials, inability to
obtain or delays in obtaining fourth party, including AOAC, or required
government approvals, the ability to meet increased market demand,
competition, protection of intellectual property, non-infringement of
intellectual property, seasonality, and other factors more fully described
in SDI's public filings with the U.S. Securities and Exchange Commission.
Company Contact:
Stan Fronczskowski
Chief Financial Officer
(302) 456-6789
http://www.sdix.com
Investor Contact:
Hayden Communications
Brett Maas (brett@haydenir.com)
(646) 536-7331
SOURCE Strategic Diagnostics Inc.
 back to top
Related links:
http://www.sdix.com
http://www.two-007.net
CONTACT:
Stan Fronczskowski, Chief Financial Officer
of Strategic Diagnostics Inc., +1-302-456-6789; or investors,
Brett Maas of Hayden Communications, +1-646-536-7331,
brett@haydenir.com, for Strategic Diagnostics Inc.
|
